<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00114361</url>
  </required_header>
  <id_info>
    <org_study_id>HBV05-01</org_study_id>
    <secondary_id>EudraCT: 2004-004736-30</secondary_id>
    <nct_id>NCT00114361</nct_id>
  </id_info>
  <brief_title>48 Weeks Combination Therapy for Patients With HBeAg-negative Chronic Hepatitis B Virus (HBV) Infection</brief_title>
  <official_title>Peginterferon Alfa-2a and Ribavirin Combination Therapy in Patients With HBeAg-negative Chronic HBV Infection (PARC Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Foundation for Liver Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Foundation for Liver Research</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate whether in patients with chronic HBeAg-negative&#xD;
      hepatitis B, PEG-IFN-ribavirin combination therapy for 1 year leads to enhanced response (HBV&#xD;
      DNA &lt;10E4 copies/ml and normal ALT 24 weeks after treatment discontinuation) in comparison&#xD;
      with pegylated interferon (PEG-IFN) monotherapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Despite the introduction of newer drugs for the treatment of chronic hepatitis B, there is&#xD;
      still no optimal treatment. Pegylated interferon alfa has proven sustained efficacy in&#xD;
      approximately 30-40% of patients with HBeAg-positive or HBeAg-negative chronic hepatitis B.&#xD;
      It is likely that combination therapy of pegylated interferon alfa with ribavirin in chronic&#xD;
      hepatitis B is more effective than pegylated interferon alfa monotherapy. In chronic&#xD;
      hepatitis C, adding ribavirin to pegylated interferon therapy doubled the sustained response&#xD;
      rate (29% vs. 56%) and has become the standard option of treatment.&#xD;
&#xD;
      To investigate the effect of the treatment with pegylated interferon and ribavirin on the&#xD;
      amount of inflammation and fibrosis in the liver, a liver biopsy will be performed within one&#xD;
      year prior to screening and at the end of follow-up.&#xD;
&#xD;
      When patients with chronic hepatitis B are treated outside any study with pegylated&#xD;
      interferon, they visit the outpatient clinic approximately every month for blood samples. So&#xD;
      in this study the amount of blood samples taken from every patient is not increased as&#xD;
      compared with treatment outside a study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2005</start_date>
  <completion_date type="Actual">April 2010</completion_date>
  <primary_completion_date type="Actual">May 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The combined presence of HBV DNA level &lt; 10E4 copies/ml and ALT normalization at the end of follow-up</measure>
    <time_frame>may 2008</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>ALT normalization</measure>
    <time_frame>May 2008</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HBV DNA negativity(undetectable by Taqman PCR)</measure>
    <time_frame>May 2008</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HBsAg loss from serum</measure>
    <time_frame>May 2008</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement liver histology</measure>
    <time_frame>May 2008</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Combined virological, biochemical and histological response</measure>
    <time_frame>May 2008</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">138</enrollment>
  <condition>Hepatitis B</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ribavirin + Peg IFN</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Peg IFN + Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin</intervention_name>
    <description>1200 mg a day, 48 weeks</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Peginterferon alpha 2a</intervention_name>
    <description>180 Âµg per week, 48 weeks</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Chronic hepatitis B&#xD;
&#xD;
          -  Biopsy performed within one year prior to screening or during screening&#xD;
&#xD;
          -  ALT &gt; 1.5 x ULN&#xD;
&#xD;
          -  HBeAg negative, anti-HBeAg positive&#xD;
&#xD;
          -  HBV DNA &gt; 10E5 copies/ml&#xD;
&#xD;
          -  Age 18-70 years&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
          -  Hepatic imaging without evidence of HCC&#xD;
&#xD;
          -  All fertile males and females must be using two forms of effective contraception&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Antiviral therapy against HBV within the previous 6 months; treatment with any&#xD;
             investigational drug within 30 days of entry to this protocol&#xD;
&#xD;
          -  Severe hepatitis activity as documented by ALT &gt; 10 x ULN&#xD;
&#xD;
          -  Advanced liver disease&#xD;
&#xD;
          -  Pre-existent leucopenia or thrombopenia&#xD;
&#xD;
          -  Co-infection with HCV,HDV or HIV&#xD;
&#xD;
          -  Other acquired or inherited causes of liver disease&#xD;
&#xD;
          -  Alpha fetoprotein &gt; 50 ng/ml.&#xD;
&#xD;
          -  Evidence of severe renal disease&#xD;
&#xD;
          -  Hyper- or hypothyroidism&#xD;
&#xD;
          -  Significant cardiovascular or pulmonary dysfunction, malignancy,immunodeficiency&#xD;
             syndromes&#xD;
&#xD;
          -  Immune suppressive treatment within the previous 6 months&#xD;
&#xD;
          -  Contra-indications for alpha-interferon therapy&#xD;
&#xD;
          -  Pregnancy, breast-feeding&#xD;
&#xD;
          -  Any medical condition requiring chronic systemic administration of steroids&#xD;
&#xD;
          -  Substance alcohol or drug abuse&#xD;
&#xD;
          -  Subjects with clinically significant retinal abnormalities&#xD;
&#xD;
          -  Subjects with clinically significant hearing abnormalities&#xD;
&#xD;
          -  Hemoglobinopathies&#xD;
&#xD;
          -  Subjects with known hypersensitivity to ribavirin&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Harry LA Janssen, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Foundation of Liver Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Erasmus MC department hepatology</name>
      <address>
        <city>Rotterdam</city>
        <zip>3000CA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>June 2010</verification_date>
  <study_first_submitted>June 14, 2005</study_first_submitted>
  <study_first_submitted_qc>June 14, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 15, 2005</study_first_posted>
  <last_update_submitted>June 18, 2010</last_update_submitted>
  <last_update_submitted_qc>June 18, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 22, 2010</last_update_posted>
  <responsible_party>
    <name_title>Prof. H.L.A. Janssen</name_title>
    <organization>Foundation for Liver reseach</organization>
  </responsible_party>
  <keyword>HBeAg-negative</keyword>
  <keyword>chronic</keyword>
  <keyword>hepatitis B</keyword>
  <keyword>viral</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Peginterferon alfa-2a</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

